Sonnet BioTherapeutics Holdings Inc [NASDAQ: SONN] surged by $0.81 during the normal trading session on Monday and reaching a high of $6.0 during the day while it closed the day at $4.73.
Sonnet BioTherapeutics Holdings Inc stock has also gained 322.32% of its value over the past 7 days. However, SONN stock has inclined by 272.44% in the 3 months of the year. Over the past six months meanwhile, it has gained 223.97% and lost -32.81% year-on date.
The market cap for SONN stock reached $14.97 million, with 3.17 million shares outstanding and 3.13 million shares in the current float. Compared to the average trading volume of 2.24M shares, SONN reached a trading volume of 30018570 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Sonnet BioTherapeutics Holdings Inc [SONN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SONN shares is $20.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SONN stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 22.31, with the Price to Cash per share for the same quarter was set at 0.65.
SONN stock trade performance evaluation
Sonnet BioTherapeutics Holdings Inc [SONN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 322.32. With this latest performance, SONN shares gained by 304.27% in over the last four-week period, additionally plugging by 223.97% over the last 6 months – not to mention a rise of 223.97% in the past year of trading.
Sonnet BioTherapeutics Holdings Inc [SONN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sonnet BioTherapeutics Holdings Inc [SONN] shares currently have an operating margin of -1376.89% and a Gross Margin at 91.31%. Sonnet BioTherapeutics Holdings Inc’s Net Margin is presently recorded at -1328.60%.
Return on Equity for this stock declined to -272.65%, with Return on Assets sitting at -272.65%.
Sonnet BioTherapeutics Holdings Inc [SONN]: Institutional Ownership
There are presently around $5.24%, or 5.32% of SONN stock, in the hands of institutional investors.
